DK4218753T3 - Ny lipasehæmmer og anvendelser deraf - Google Patents

Ny lipasehæmmer og anvendelser deraf

Info

Publication number
DK4218753T3
DK4218753T3 DK22197886.9T DK22197886T DK4218753T3 DK 4218753 T3 DK4218753 T3 DK 4218753T3 DK 22197886 T DK22197886 T DK 22197886T DK 4218753 T3 DK4218753 T3 DK 4218753T3
Authority
DK
Denmark
Prior art keywords
applications
lipase inhibitor
new lipase
new
inhibitor
Prior art date
Application number
DK22197886.9T
Other languages
Danish (da)
English (en)
Inventor
Sampath-Kumar Anandan
Kevin Greenman
Zeeshan Kamal
Vijay P Singh
Original Assignee
Mayo Found Medical Education & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Found Medical Education & Res filed Critical Mayo Found Medical Education & Res
Application granted granted Critical
Publication of DK4218753T3 publication Critical patent/DK4218753T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/10Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
    • C07D305/12Beta-lactones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
DK22197886.9T 2017-07-12 2018-07-12 Ny lipasehæmmer og anvendelser deraf DK4218753T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762531454P 2017-07-12 2017-07-12
EP18831486.8A EP3651784B1 (en) 2017-07-12 2018-07-12 Compounds for the reducing lipotoxic damage

Publications (1)

Publication Number Publication Date
DK4218753T3 true DK4218753T3 (da) 2026-03-09

Family

ID=65002124

Family Applications (1)

Application Number Title Priority Date Filing Date
DK22197886.9T DK4218753T3 (da) 2017-07-12 2018-07-12 Ny lipasehæmmer og anvendelser deraf

Country Status (14)

Country Link
US (5) US11339126B2 (https=)
EP (2) EP3651784B1 (https=)
JP (1) JP7224331B2 (https=)
KR (1) KR102679975B1 (https=)
CN (1) CN111343999B (https=)
AU (2) AU2018300985B2 (https=)
BR (1) BR112020000635B1 (https=)
CA (1) CA3069526A1 (https=)
DK (1) DK4218753T3 (https=)
ES (1) ES2934883T3 (https=)
IL (1) IL271884B2 (https=)
PL (2) PL4218753T3 (https=)
SG (1) SG11202000239XA (https=)
WO (1) WO2019014434A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202000239XA (en) 2017-07-12 2020-02-27 Mayo Found Medical Education & Res Compounds for the reducing lipotoxic damage
MX2023012532A (es) * 2021-04-23 2023-11-29 Panafina Inc Metodos de sintetizacion de derivados de lipstatina.
CN114560887B (zh) * 2022-02-15 2024-01-26 安徽美致诚药业有限公司 一种制备奥利司他的中间体的制备方法
AU2023243617A1 (en) * 2022-03-31 2024-10-03 Mayo Foundation For Medical Education And Research Methods and materials for treating pancreatic diseases and disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA859575B (en) * 1984-12-21 1986-08-27 Hoffmann La Roche Oxetanones
CA1270837A (en) * 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
IL97148A (en) * 1990-02-26 1996-11-14 Hoffmann La Roche Oxetanones a process for their manufacture and pharmaceutical compositions containing them
FR2754827B1 (fr) 1996-10-17 1998-12-24 Biocem Lipases pancreatiques et/ou colipases recombinantes et polypeptides dervies produits par les plantes, leurs procedes d'obtention et leurs utilisations
FR2758143B1 (fr) 1997-01-07 1999-02-19 Laphal Laboratoire De Pharmaco Inhibiteurs specifiques de la lipase pancreatique et leurs applications
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20040018197A1 (en) 2002-04-26 2004-01-29 Promega Corporation Treatment for weight loss
DE102004009076A1 (de) 2004-02-23 2005-10-27 Solvay Pharmaceuticals Gmbh Alkylcarbamat-substituierte β-Lactone, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP1803714A1 (en) 2005-12-27 2007-07-04 KRKA, tovarna zdravil, d.d., Novo mesto Process for preparing crystalline forms of orlistat
WO2009059046A1 (en) 2007-10-31 2009-05-07 Burnham Institute For Medical Research Beta-lactone compounds
US9023887B2 (en) 2011-04-15 2015-05-05 University of Pittsburgh—of the Commonwealth System of Higher Education Lipase inhibitors for the treatment of pancreatitis and organ failure
US20150099800A1 (en) 2012-05-24 2015-04-09 Northeastern University Novel lipase inhibitors, reporter substrates and uses thereof
CN106470804B (zh) 2014-06-30 2019-09-10 工机控股株式会社 电动工具
WO2016102541A1 (en) 2014-12-22 2016-06-30 Université Libre de Bruxelles Composition comprising vancomycin and orlistat
US20180319894A1 (en) 2015-11-03 2018-11-08 Mayo Foundation For Medical Education And Research Using colipase inhibitors to treat pancreatitis
SG11202000239XA (en) 2017-07-12 2020-02-27 Mayo Found Medical Education & Res Compounds for the reducing lipotoxic damage

Also Published As

Publication number Publication date
US11976040B2 (en) 2024-05-07
EP4218753A3 (en) 2023-10-11
US11339126B2 (en) 2022-05-24
PL3651784T3 (pl) 2023-06-19
US20250340512A1 (en) 2025-11-06
US20230250057A1 (en) 2023-08-10
RU2020105488A3 (https=) 2021-08-27
EP4218753B1 (en) 2025-12-03
AU2018300985A1 (en) 2020-01-30
AU2018300985B2 (en) 2024-09-12
JP2020527138A (ja) 2020-09-03
EP4218753A2 (en) 2023-08-02
WO2019014434A1 (en) 2019-01-17
CN111343999B (zh) 2022-03-01
ES2934883T3 (es) 2023-02-27
SG11202000239XA (en) 2020-02-27
CN111343999A (zh) 2020-06-26
IL271884A (en) 2020-02-27
EP3651784A1 (en) 2020-05-20
EP3651784A4 (en) 2021-05-05
IL271884B2 (en) 2023-07-01
RU2020105488A (ru) 2021-08-12
EP3651784B1 (en) 2022-09-28
US20210139421A1 (en) 2021-05-13
CA3069526A1 (en) 2019-01-17
US20240343688A1 (en) 2024-10-17
AU2024278291A1 (en) 2025-01-09
KR102679975B1 (ko) 2024-06-28
US11623915B2 (en) 2023-04-11
PL4218753T3 (pl) 2026-04-20
US12325690B2 (en) 2025-06-10
BR112020000635B1 (pt) 2023-04-18
IL271884B1 (en) 2023-03-01
BR112020000635A2 (pt) 2020-07-14
JP7224331B2 (ja) 2023-02-17
US20220324797A1 (en) 2022-10-13
KR20200027975A (ko) 2020-03-13

Similar Documents

Publication Publication Date Title
IL289612A (en) Hpk1 inhibitors and uses thereof
DK4480953T3 (da) Tyk2-hæmmere og anvendelser deraf
EP3805217A4 (en) ERK INHIBITOR AND ITS USE
EP4003319A4 (en) HDAC6 INHIBITORS AND THEIR USES
IL283106A (en) Erk inhibitors and uses thereof
DK3658557T3 (da) Tyk2-inhibitorer og anvendelser deraf
IL282090A (en) Tyk2 inhibitors and uses thereof
DK3610005T3 (da) Peptidligase og anvendelse deraf
DK3485010T3 (da) Bacillus cibi-dnase-varianter og anvendelser deraf
EP3670513A4 (en) FGFR INHIBITOR AND MEDICAL APPLICATION OF IT
DK3897833T3 (da) Hæmmere af APOL1 og fremgangsmåder til anvendelse heraf
EP3746071A4 (en) GCN2 INHIBITORS AND THEIR USES
DK3668512T3 (da) Pyruvatkinasemodulatorer og anvendelse deraf
EP3572400C0 (en) EZH2 INHIBITOR AND ITS USE
DK3389658T3 (da) Glycosidasehæmmere og anvendelser deraf
DK3559227T3 (da) Proteasevarianter og anvendelser deraf
EP3606519A4 (en) ASK1 INHIBITOR COMPOUNDS AND ASSOCIATED USES
DK3710430T3 (da) Acss2-inhibitorer og fremgangsmåder til anvendelse deraf
DK3621694T3 (da) Lrrc33-inhibitorer og anvendelse heraf
DK3474883T3 (da) Komplementinhibitorer og anvendelser deraf
DK3543240T3 (da) URAT1-inhibitor og anvendelse deraf
DK3490988T3 (da) Ny forbindelse og fremgangsmåde
IL291217A (en) Usp30 inhibitors and uses thereof
DK3532459T3 (da) Lsd1-hæmmere og medicinske anvendelser deraf
EP3595665A4 (en) DUAL MAGL AND FAAH INHIBITORS